Teva to acquire Gecko Health Innovations

JERUSALEM and CAMBRIDGE, Mass. — Teva Pharmaceutical on Friday announced that it entered into a definitive agreement to acquire Gecko Health Innovations, which focuses on developing software and product solutions to aid in compliance and adherence improvement in the management of respiratory diseases.



"The acquisition of Gecko Health Innovations further enhances Teva's ability to develop and deliver truly patient-centered solutions by utilizing e-connected, data-driven technology to improve the management of respiratory diseases," said Rob Koremans, president and CEO of Teva Global Specialty Medicines.



Through the agreement, Teva will acquire CareTRx, a cloud-based solution developed by Gecko Health Innovations to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools. CareTRx is comprised of a hardware device that attaches to most metered-dose inhalers, as well as a software program which synchronizes and stores data through an app-based user interface.  



"During the last three years, we have designed and built a system to support respiratory disease management by intuitively connecting caregivers, patients and families," said Dr. Yechiel Engelhard, CEO and founder of Gecko Health Innovations. "In founding Gecko Health Innovations, our vision was to connect chronic medication management into one platform, leveraging this information to support and empower patients by partnering with leading players in the health care and pharmaceutical industries. We are very excited to realize this vision as it aligns to Teva's focus on innovative patient solutions."